DBMR published a research report on “Myasthenia Gravis Disease Market” –Industry Analysis, Size, Share, Growth, Trends and Forecast to 2027. Myasthenia Gravis Disease Market report provides analysis ...
Efgartigimod significantly reduced immunoglobulin use, with 95% reduction in annual courses and 84-97% of patients stopping use post-initiation. Hospitalizations, exacerbations, and crisis events ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results